Feedback controlled release

• US 4,952,406 A
• Filed: 04/03/1987
• Issued: 08/28/1990
• Est. Priority Date: 06/27/1985
• Status: Expired due to Fees

• Current Assignee: Children's Medical Center Corporation
• Original Assignee: Children's Medical Center Corporation
• Inventors: Brown, Larry, Fischel-Ghodsian, Fariba, Langer, Robert S.
• Primary Examiner(s): WADDELL, FREDERICK
• Application Number:
  US07/036,158
• Time in Patent Office: 1,243 Days
• Field of Search: 514/3, 424/425, 424/2
• US Class Current: 514/425
• CPC Class Codes: A61K 38/28 Insulins
• CPC Class Codes: A61K 9/0024 Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L
• CPC Class Codes: C12N 11/10 the carrier being a carbohydrate

Abstract

A controlled release system using a feedback-responsive controller reversibly changes the pH of the aqueous microenvironment of a biologically active compound sequestered in an aqueous-fluid-penetrable, aqueous-insoluble biocompatible material; the pH change is effected in response to a change in the concentration of the target compound in the aqueous medium surrounding the insoluble material; as a result of the pH change, the aqueous solubility and therefore the release rate of the active compound is reversibly changed.

Claims

1. A system providing feedback-responsive release of a protein to an aqueous biological fluid, wherein said protein participates in changing the concentration of a component of said fluid, said system comprising:

(a) said protein, which is selected to have an aqueous solubility at a first level when the pH of the aqueous microenvironment of said protein is in a first pH range, and an aqueous solubility at a second level higher than the first level when said microenvironment pH is in a second pH range;

(b) an aqueous-insoluble biocompatible material positioned to sequester said protein, said protein and said insoluble material being characterized in that said insoluble material is aqueous-fluid-penetrable, allowing controlled release of said sequestered protein therefrom, and changes in said aqueous solubility from said first to said second level effecting an increase in the rate of release of said sequestered protein from said insoluble biocompatible material; and

(c) an enzyme catalyzing a reaction capable of causing the pH of the microenvironment of said sequestered protein to change between said first pH range and said second pH range, responsive to concentration changes of said component in said aqueous biological fluid,

said enzyme and said protein being further characterized in that concentrations of said component characteristic of an increased demand for said protein in said biological fluid cause the enzyme to change said microenvironment pH from said first pH range to said second pH range.

2. The system of claim 1 wherein said enzyme is sequestered by said insoluble material, and wherein a signal representative of said component concentration is capable of communicating between aqueous medium surrounding said insoluble phase and said enzyme.

3. The system of claim 2 wherein said signal comprises said component, and an increase in said component concentration causes said enzyme to change said pH from said first pH range to said second pH range.

4. The system of claim 1 wherein said component comprises a substrate for said enzyme;

wherein said enzyme catalyzes formation of a product from said substrate, said product effecting said pH change.

5. The system of claim 2 wherein said insoluble material is an aqueous-permeable membrane that is permeable to said dissolved protein, but not permeable to said enzyme, and agglomerated protein being contained within said membrane.

6. The system of claim 2 wherein said insoluble material is a polymer matrix, said protein and said enzyme being interspersed therein.

7. The system of claim 6 wherein said polymer matrix is selected from ethylene vinyl acetate copolymer, nitrocellulose, silicone, hydrogels, poly-2-hydroxy ethyl methylmethacrylate, polyesters, and polyurethanes.

8. The system of claim 1 wherein said insoluble material is selected from an ethylene vinyl acetate copolymer.

12. The system of claim 1 wherein said system is adapted to be implanted, in vivo, in a mammal.

13. The system of claim 12 wherein said protein is a hormone.

14. The system of claim 13 wherein said hormone is selected from insulin, glucagon, growth hormone, lutinizing hormone, and releasing hormone.

15. The system of claim 6 wherein said protein is agglomerated and its ability to pass through said polymer matrix is restricted by said agglomeration.

16. The system of claim 15 wherein said pH change alters the ability of said protein to pass through said matrix.

17. The system of claim 1 wherein said protein is an insulin.

18. The system of claim 1 wherein said component is glucose, and said enzyme catalyzes a reaction of glucose that changes said microenvironment pH from said first range to said second range.

19. The system of claim 1 or claim 18 wherein said protein is an insulin having an isoelectric point of pH 7.0 or greater.

20. The system of claim 19 wherein said modified insulin is trilysine insulin or triglycine insulin.

21. The system of claim 19 wherein said first pH range is around the isoelectric point of said insulin and said second pH range is under 7.0.

22. The system of claim 1 wherein said component is glucose.

23. The system of claim 18 wherein said enzyme comprises glucose oxidase and catalyses production of gluconic acid from glucose.

24. The system of claim 23 wherein said first pH range is 7.5-7.1 and said second pH range is under 7.0.

25. The system of claim 23 wherein said system further comprises a means for reducing the concentration of hydrogen peroxide produced by glucose oxidase.

9. A system providing feedback-responsive release of an insulin to an aqueous biological fluid, said system comprising,

(a) an insulin having an isoelectric point of pH 7.0 or greater;

(b) an aqueous insoluble biocompatible material positioned to sequester said insulin, said insoluble biocompatible material being characterized in that it is aqueous-fluid-penetrable, release of said insulin from said biocompatible material being directly related to insulin solubility; and

(c) an enzyme that operates in the presence of glucose to increase the solubility of said insulin.

10. The system of claim of claim 9 in which said enzyme is glucose oxidase and the insulin is modified to increase its isoelectric point.

11. The system of claim 10 further comprising polylactic acid.